PolyPid Advances D-PLEX₁₀₀ Toward FDA Approval with Rolling NDA Submission
Event summary
- PolyPid initiated a rolling NDA submission for D-PLEX₁₀₀ to prevent surgical site infections in colorectal surgery patients.
- First modules submitted under FDA’s Fast Track designation; completion expected by Q2 2026.
- D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in SSI incidence in the Phase 3 SHIELD II trial.
- Company is negotiating U.S. commercialization partnerships alongside regulatory progress.
The big picture
PolyPid’s NDA submission for D-PLEX₁₀₀ marks a critical step in addressing surgical site infections, an area with significant unmet medical needs. The FDA’s Fast Track designation and positive Phase 3 trial results position the company to potentially disrupt the infection prevention market if approved. Success could validate PolyPid’s controlled-release drug delivery technology beyond colorectal surgery.
What we're watching
- Regulatory Timing
- Whether the FDA’s rolling review will expedite approval and avoid delays in Q2 2026.
- Commercialization Strategy
- How PolyPid’s U.S. partnership negotiations progress alongside regulatory milestones.
- Market Adoption
- The pace at which D-PLEX₁₀₀ could gain traction if approved, given its Breakthrough Therapy Designation.
Related topics